#USA #New York #Bronstein Gewirtz #Actinium Pharmaceuticals #ATNM

Investor Alert: Class Action Against Actinium Pharmaceuticals

In a significant legal development, Bronstein, Gewirtz & Grossman LLC, a law firm recognized nationally for its shareholder representation, is calling on investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) to consider joining a recently initiated class action lawsuit. This lawsuit arises in response to substantial losses sustained by investors during a specific time frame, ranging from March 31, 2022, to August 2, 2024. According to the lawsuit, the claims are based on alleged violations of federal securities laws and the purportedly misleading behavior of the company and its executives during the said period.

Class Definition

The class action lawsuit is designed to represent all individuals and entities that purchased or otherwise acquired Actinium securities during the designated class period. As part of this legal action, plaintiffs assert that Actinium's management has made materially false statements, leading investors to believe that the FDA was highly likely to approve the company’s Biologics License Application (BLA) for its drug, Iomab-B. The implications of these statements suggest a significant level of miscommunication regarding the status and future of the drug and its trials.

Allegations Against Actinium

The complaint highlights alarming details concerning the Phase 3 Sierra trial results. Investors in Actinium were repeatedly informed of the trial's positive Complete Remission data; however, what was less clearly communicated were the concerning lack of statistically significant or clinically meaningful Overall Survival (OS) data. The lawsuit indicates that the company's executives misled investors about the implications of this OS data, asserting that the FDA had essentially approved the trial’s design despite the poor survival results.

Such statements created a false sense of security among investors about the drug's approval and future prospects, fostering an atmosphere of confidence that was evidently misplaced. Thus, the class action aims to hold these officials accountable for the potentially deceptive nature of their communications and actions that may have resulted in substantial financial losses for the investors.

Next Steps

Those who have been impacted by the fluctuations in Actinium’s stock prices and believe they were misled are encouraged to join this class action lawsuit. Interested individuals may obtain further insights and a broad outline of the complaint by visiting the law firm’s website, bgandg.com/ATNM. Those considering action must act quickly; the deadline to request the court to appoint them as lead plaintiffs is May 26, 2025. Importantly, participation in the lawsuit and any potential recovery does not mandate serving as a lead plaintiff, thereby lowering the barrier for others wishing to join.

Financial Considerations

Importantly, the law firm outlines that there is no financial risk for the investors who decide to join this class action lawsuit. They operate under a contingency fee basis, meaning that attorneys' fees and any out-of-pocket expenses would only be covered from a successful recovery in the lawsuit. This ensures that no upfront costs are imposed upon the investors who may already be dealing with financial distress due to the alleged mismanagement of the company.

Why Choose Bronstein, Gewirtz & Grossman?

Bronstein, Gewirtz & Grossman LLC is recognized for its extensive track record in recovering losses for investors in securities fraud and derivative lawsuits across the nation, totaling hundreds of millions of dollars. The firm offers continued support to the investors through various platforms, including updates via LinkedIn and social media channels.

Actinium Pharmaceuticals' situation serves as a compelling reminder of the importance of transparency and accountability within publicly traded companies. Investors who believe they were misled now have the opportunity to take legal action and possibly reclaim their losses through a cooperative class effort.